What changed from existing technology?
This study looked at how well and safely a drug called upadacitinib works for treating Crohn's disease in people from East Asia.
This is the first study to specifically analyze the effectiveness and safety of upadacitinib in East Asian patients with Crohn's disease.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
cacy and safety of upadacitinib for Crohn’s disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies. Abstract Background Upadaciti
Title ↗OpenAlex author affiliations: AbbVie (United States)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
Upadacitinib may be considered for treating Crohn's disease in East Asian populations, based on its demonstrated efficacy and safety in this analysis.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchEfficacy and safety of upadacitinib for Crohn’s disease in patients in East Asia: a post hoc analysis of randomized phase 3 studiesJournal of Gastroenterology · Published 2026-08-30 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.